Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

CME

CME Group Q1 Revenue Up 14% to $1.9B

CME Group reported first-quarter 2026 revenue of $1.9 billion, up 14% from the prior-year period, as trading activity hit a record and pushed several key metrics to new highs.

Net income rose 20% to $1.2 billion, while diluted earnings per share also increased 20% to $3.18. On an adjusted basis, diluted earnings per share came in at $3.36, also up 20% from a year earlier. Adjusted net income was $1.2 billion and adjusted operating income was $1.4 billion.

Average daily volume climbed 22% to a quarterly record 36.2 million contracts, with records across all six asset classes. Non-U.S. average daily volume reached 11.4 million contracts, up 30% from the same quarter in 2025. Within that, APAC volume rose 33% and EMEA volume increased 29%.

Clearing and transaction fees revenue set a record at $1.5 billion. Market data revenue also reached a record, totaling $224 million. The average rate per contract was $0.652.

The company ended March 31 with $2.6 billion in cash, including $200 million deposited with Fixed Income Clearing Corporation, and $3.4 billion of debt. During the quarter, CME paid about $2.7 billion in dividends and repurchased $536 million of common shares.

CME said average daily margin savings topped $85 billion, another record. As a result of these announcements, the company's shares have moved 1.24% on the market, and are now trading at a price of $297.58. For the full picture, make sure to review CME GROUP INC.'s 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS